## Abstract Although some cardiac effects, such as palpitations and tachycardia, occur commonly in healthy people, they have also been shown to be associated with agents used to treat the myeloproliferative disorders. Various strategies exist to prevent and manage cardiac effects and minimise their
Myeloproliferative disorder therapy: assessment and management of adverse events—a dermatologist's perspective
✍ Scribed by Boutros Soutou; Sélim Aractingi
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 106 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0278-0232
- DOI
- 10.1002/hon.912
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Development of cutaneous manifestations in patients with myeloproliferative disorders can be either due to the course of the disease itself or induced by some of the treatments given. The cutaneous manifestations may reveal an unknown haemopathy and/or indicate a poor prognosis. Some of these alter quality of life. Hydroxyurea has been shown to induce a variety of cutaneous adverse reactions ranging from benign effects such as hyperpigmentation to more severe leg ulcers and squamous cell carcinomas. Herein, we discuss the importance of undertaking regular physical examinations in order to identify and treat cutaneous manifestations early in their course. Copyright © 2009 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract Chronic diseases such as the myeloproliferative disorders may mask a worsening emotional state in patients, which can be exacerbated by the addition of common treatments such as interferon‐__α__. Management of mood disturbances is best considered from the first consultation, as the nega
## Abstract The authors investigated the relationship between childhood abuse and obesity in young adulthood (M age = 22) in a large, U.S. representative sample (N = 15,197). Controlling for demographics and depression, men with a history of childhood sexual abuse were at increased risk of overweig